1. Home
  2. GNPX vs VVOS Comparison

GNPX vs VVOS Comparison

Compare GNPX & VVOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$0.77

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Logo Vivos Therapeutics Inc.

VVOS

Vivos Therapeutics Inc.

HOLD

Current Price

$0.62

Market Cap

9.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNPX
VVOS
Founded
2009
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
9.7M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
GNPX
VVOS
Price
$0.77
$0.62
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$2.75
AVG Volume (30 Days)
708.5K
184.8K
Earning Date
05-11-2026
04-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
6.76
EPS
N/A
N/A
Revenue
N/A
$17,443,000.00
Revenue This Year
N/A
$69.66
Revenue Next Year
N/A
$48.38
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.05
52 Week Low
$0.14
$0.58
52 Week High
$12.97
$7.40

Technical Indicators

Market Signals
Indicator
GNPX
VVOS
Relative Strength Index (RSI) 25.43 29.38
Support Level $0.15 N/A
Resistance Level $2.12 $1.50
Average True Range (ATR) 0.06 0.07
MACD 0.02 0.00
Stochastic Oscillator 8.39 9.00

Price Performance

Historical Comparison
GNPX
VVOS

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

About VVOS Vivos Therapeutics Inc.

Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.

Share on Social Networks: